[go: up one dir, main page]

TW247876B - Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection - Google Patents

Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection

Info

Publication number
TW247876B
TW247876B TW083101381A TW83101381A TW247876B TW 247876 B TW247876 B TW 247876B TW 083101381 A TW083101381 A TW 083101381A TW 83101381 A TW83101381 A TW 83101381A TW 247876 B TW247876 B TW 247876B
Authority
TW
Taiwan
Prior art keywords
hiv
infection
prevention
pharmaceutical compositions
treating
Prior art date
Application number
TW083101381A
Other languages
English (en)
Inventor
Alexander R Neurath
Asim Kumar Debnath
Shibo Jiang
Original Assignee
New York Blood Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Ct Inc filed Critical New York Blood Ct Inc
Application granted granted Critical
Publication of TW247876B publication Critical patent/TW247876B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW083101381A 1993-12-28 1994-02-18 Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection TW247876B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17466293A 1993-12-28 1993-12-28

Publications (1)

Publication Number Publication Date
TW247876B true TW247876B (en) 1995-05-21

Family

ID=32174281

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083101381A TW247876B (en) 1993-12-28 1994-02-18 Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection

Country Status (2)

Country Link
US (1) US6727240B1 (zh)
TW (1) TW247876B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
US8450368B2 (en) * 2006-07-24 2013-05-28 University Of Maryland, Baltimore Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy
KR20110065549A (ko) * 2008-10-03 2011-06-15 샬롯테-맥클렌버그 하스피털 오쏘러티 두잉 비지니스 에즈 카롤리나스 메디컬 센터 메탈로포르피린을 이용한 ｃ형 간염의 치료 방법
EA037850B1 (ru) 2013-08-29 2021-05-27 Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Способы и композиции для рнк-направленного лечения вич-инфекции
WO2021188787A1 (en) * 2020-03-19 2021-09-23 Renibus Therapeutics, Inc. Method for treatment of coronavirus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570143B2 (en) 1985-01-14 1988-03-03 Rockefeller University, The Method of increasing heme excretion from a mammal using tin protoporphyrin
US4692440A (en) 1985-03-25 1987-09-08 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4782049A (en) 1986-12-08 1988-11-01 The Rockefeller University Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis
EP0337598A3 (en) 1988-02-26 1991-07-03 Georgia State University Foundation, Inc. Use of porphyrins and metalloporphyrins in the treatment of diseases caused by human immunodeficiency viruses
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
US5192788A (en) 1988-05-23 1993-03-09 Georgia State University Foundation, Inc. Porphyrin antiviral compositions
JPH05504774A (ja) 1990-07-31 1993-07-22 ザ ロックフェラー ユニバーシティ エイズ治療を増進するためのメタロポルフィリン類の使用
US5230998A (en) 1991-07-25 1993-07-27 Neurath Alexander R Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp 120

Also Published As

Publication number Publication date
US6727240B1 (en) 2004-04-27

Similar Documents

Publication Publication Date Title
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
MY117892A (en) Therapeutic compounds
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
EP0490667A3 (en) Hiv protease inhibitors
DE69431972D1 (de) HIV Protease Hemmer in pharmazeutischen Zusammensetzungen zur Behandlung von AIDS
GR3036774T3 (en) Compositions containing G-CSF and TNF binding protein.
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
TW247876B (en) Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
ZA991029B (en) Composition and methods for treatment of hiv infections.
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
MX9805441A (es) Compuestos terapeuticos.
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
MY119513A (en) Pharmaceutical compositions comprising lamivudine and zidovudine
IE883793L (en) Method of inhibiting human immunodeficiency virus
IL106491A0 (en) Anti viral preparations
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
CA2142862A1 (en) Method for Inhibiting HIV Replication Using IL-4
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus